Emma Reeve

Ms. Reeve has over 20 years of global financial experience across pharmaceutical, medical device and bio-pharma companies. She currently serves as the Chief Financial Officer of Constellation Pharmaceuticals, Inc. In this role, Ms. Reeve ensured the Company was well-capitalized, and oversaw Constellation’s initial public offering in July 2018. Prior to Constellation, Ms. Reeve acted as interim Chief Financial Officer and Corporate Controller of PAREXEL International, a global biopharmaceutical services company, where she was responsible for all aspects of finance, investor relations, procurement and facilities, leading a team of over 950 people. In this role she led the finance aspects of a sell-side process which culminated in an agreement to take the company private in a $5Bn leveraged buy-out. Ms. Reeve previously served as Chief Financial Officer of both Inotek Pharmaceuticals and Aton Pharma. She held senior finance and operational roles at Bristol-Myers Squibb, Merck and Novartis.